moxifloxacin

(redirected from Moxifloxacin hydrochloride)
Also found in: Medical.

mox·i·flox·a·cin

 (mŏk′sĭ-flŏk′sə-sĭn)
n.
An antibiotic drug of the fluoroquinolone class, C21H24FN3O4, used primarily to treat respiratory, sinus, and skin infections.

[m(eth)- + alteration of oxy- + -floxacin, fluoroquinolone suff.; see ciprofloxacin.]
Translations

moxifloxacin

n moxifloxacino, moxifloxacina
References in periodicals archive ?
Additionally, the company's Moxifloxacin Hydrochloride 400mg, which is an anti-infective, was also granted approval by the US FDA.
In an advisory, the FDA said these unregistered drug products are Moxifloxacin Hydrochloride (Moxibright) 5 mL Eye Drops, Moxifloxacin Hydrochloride + Dexamethasone Sodium Phosphate (Moxibright DM) 5 mL Eye Drops, Carboxymethyl Cellulose Sodium + Glycerin (Tearbright Plus) 10 mL Eye Drops, Gatifloxacin + Prednisolone Acetate (Gatsun-P) 5 mL Eye Drops and Moxifloxacin Hydrochloride (Occumox) 5 mL Eye Drops.
Moxifloxacin hydrochloride (MOX) reference standard was provided by Sabaa, Kahira Company, Egypt, and its purity was 100.01 [+ or -] 0.707%.
A validated RP-HPLC method for the analysis of moxifloxacin hydrochloride in pharmaceutical dosage forms.
(TSE: 4507) today announced the Japan launch of "Avelox(R) Tablet 400mg (moxifloxacin hydrochloride), a new quinolone antibacterial licensed from Bayer Yakuhin, Ltd.
has announced Health Canada's approval of Avelox(R) (moxifloxacin hydrochloride), a new antibiotic designed to rapidly treat patients suffering with common respiratory tract infections (RTIs).
Mylan NV (NASDAQ, TASE: MYL), a global pharmaceutical company, has launched its Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 250 mL single-dose flexible bags, the first AP-rated generic version of Bayer's Avelox, in the United States, it was reported yesterday.
Reddy's reports market availibility of US FDA approved Moxifloxacin Hydrochloride Tablets 400 mg